JP2011526693A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526693A5
JP2011526693A5 JP2011516713A JP2011516713A JP2011526693A5 JP 2011526693 A5 JP2011526693 A5 JP 2011526693A5 JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011526693 A5 JP2011526693 A5 JP 2011526693A5
Authority
JP
Japan
Prior art keywords
determinants
tumor
subject
determinant
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011516713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048862 external-priority patent/WO2009158620A2/en
Publication of JP2011526693A publication Critical patent/JP2011526693A/ja
Publication of JP2011526693A5 publication Critical patent/JP2011526693A5/ja
Withdrawn legal-status Critical Current

Links

JP2011516713A 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法 Withdrawn JP2011526693A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
US61/075,933 2008-06-26
PCT/US2009/048862 WO2009158620A2 (en) 2008-06-26 2009-06-26 Signatures and determinants associated with metastasis methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011526693A JP2011526693A (ja) 2011-10-13
JP2011526693A5 true JP2011526693A5 (enExample) 2012-05-31

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516713A Withdrawn JP2011526693A (ja) 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法

Country Status (14)

Country Link
US (1) US20110182881A1 (enExample)
EP (1) EP2307886A2 (enExample)
JP (1) JP2011526693A (enExample)
KR (1) KR20110036056A (enExample)
CN (1) CN102132160A (enExample)
AU (1) AU2009262022A1 (enExample)
BR (1) BRPI0914734A2 (enExample)
CA (1) CA2728674A1 (enExample)
IL (1) IL210245A0 (enExample)
MX (1) MX2010014280A (enExample)
NZ (1) NZ590385A (enExample)
RU (1) RU2011102743A (enExample)
WO (1) WO2009158620A2 (enExample)
ZA (1) ZA201100225B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US12680139B2 (en) 2009-01-07 2026-07-14 Myriad Genetics, Inc. Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9606057B2 (en) 2010-06-01 2017-03-28 Todos Medical Ltd. Biochemical analysis of PBMC
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2012061721A1 (en) * 2010-11-05 2012-05-10 Alleghney-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
EP2707710B1 (en) 2011-05-11 2022-08-17 Todos Medical Ltd. Diagnosis of cancer based on infrared spectroscopic analysis of dried blood plasma samples
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
CN104684398A (zh) 2012-08-31 2015-06-03 索隆-基特林癌症研究协会 粒子、方法以及其用途
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
EP2934600A4 (en) 2012-12-19 2016-08-17 Sloan Kettering Inst Cancer MULTIMODAL PARTICLES, METHOD THEREFOR AND USES THEREOF
EP2958481A4 (en) * 2013-02-20 2017-03-08 Sloan-Kettering Institute for Cancer Research Wide field raman imaging apparatus and associated methods
NZ712575A (en) 2013-03-14 2019-08-30 Castle Biosciences Inc Methods for predicting risk of metastasis in cutaneous melanoma
US9804145B2 (en) 2013-05-28 2017-10-31 Todos Medical Ltd. Infrared analysis of benign tumors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
WO2015132672A2 (en) * 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016018896A1 (en) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
CA2976769C (en) * 2015-02-17 2023-06-13 Siemens Healthcare Diagnostics Inc. Model-based methods and apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
EP3317035A1 (en) 2015-07-01 2018-05-09 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
EP3532641A4 (en) * 2016-10-28 2020-06-17 Mao Ying Genetech Inc. METHOD FOR IDENTIFYING THE PRIMARY LOCATION OF METASTASING CANCER AND SYSTEM THEREFOR
CN111094594A (zh) * 2017-07-17 2020-05-01 茂英基因科技股份有限公司 产生复数候选探针和鉴定哺乳动物中细胞类型的方法
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
US20230092508A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230767A (en) * 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
JP2005532780A (ja) * 2001-09-19 2005-11-04 インタージェネティックス インコーポレイテッド 発癌リスク層別化のための遺伝的解析
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
US20050282196A1 (en) * 2004-04-30 2005-12-22 Jose Costa Methods and compositions for cancer diagnosis
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
CA2629793A1 (en) * 2005-11-16 2007-05-24 Marsha A. Moses Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090069196A1 (en) * 2006-03-22 2009-03-12 Mathias Gehrmann Prediction of Breast Cancer Response to Chemotherapy
WO2008030986A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
EP2215261B1 (en) * 2007-10-23 2018-02-21 Clinical Genomics Pty Ltd A method of diagnosing neoplasms
CA2714521A1 (en) * 2008-02-14 2009-08-20 Decode Genetics Ehf Susceptibility variants for lung cancer
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
WO2009140556A2 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
EP4350001A3 (en) * 2009-11-23 2024-06-19 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Similar Documents

Publication Publication Date Title
RU2011102743A (ru) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
Zaha Significance of immunohistochemistry in breast cancer
JP2011528442A5 (enExample)
JP5750152B2 (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP2020126077A (ja) Ｓｔ２心臓バイオマーカのための検査装置および方法
JP2018504609A5 (enExample)
JP2013505429A5 (enExample)
US20170089903A1 (en) Biomarkers for detection of breast cancer in women with dense breasts
EP2979096B1 (en) Integrin alpha-v-beta 6 for diagnosis/prognosis of colorectal carcinoma
Rutledge et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection
JP2010535014A5 (enExample)
JP2021523379A5 (enExample)
CN106662543A (zh) 肺癌患者中的非侵入性基因突变检测
ES2551713T3 (es) Procedimientos para el diagnóstico o pronóstico de cáncer colorrectal
Li et al. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
JP2012526543A5 (enExample)
JP2025518766A (ja) 胃癌発病可能性の予測のためのバイオマーカー及びその用途
Innaro et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
Tay et al. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer
CN106383231B (zh) 一种诊断肝癌的标记物组合及其应用
US7951544B1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
KR20240157611A (ko) 전이성 유방암의 항암제 치료 반응성 및 예후 예측용 신규한 바이오마커 및 이의 용도
CN119630966A (zh) 用于对膀胱癌进行风险分层和管理的方法和系统
KR102136747B1 (ko) 장형 위암의 예후 진단 마커
JP7239139B2 (ja) 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法